In this context, our experiments showing that blockade of Fcmr on myeloid cells synergizes with T cell-specific anti-PD1 treatment to reduce B16 melanoma growth suggest that therapeutic targeting of Fcmr may be a promising strategy for patients that do not respond to currently available immunotherapies. This evidence concerns the gene FCMR and melanoma.